Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 180 entries
Sorted by: Best Match Show Resources per page
Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation.

HeartRhythm case reports

Albakri A, Klingenheben T.
PMID: 28948151
HeartRhythm Case Rep. 2017 Jul 21;3(9):440-442. doi: 10.1016/j.hrcr.2017.07.003. eCollection 2017 Sep.

No abstract available.

Cite
Albakri A, Klingenheben T. Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation. HeartRhythm Case Rep. 2017;3(9):440-442doi: 10.1016/j.hrcr.2017.07.003.
Albakri, A., & Klingenheben, T. (2017). Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation. HeartRhythm case reports, 3(9), 440-442. https://doi.org/10.1016/j.hrcr.2017.07.003
Albakri, Aref, and Klingenheben, Thomas. "Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation." HeartRhythm case reports vol. 3,9 (2017): 440-442. doi: https://doi.org/10.1016/j.hrcr.2017.07.003
Albakri A, Klingenheben T. Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation. HeartRhythm Case Rep. 2017 Jul 21;3(9):440-442. doi: 10.1016/j.hrcr.2017.07.003. eCollection 2017 Sep. PMID: 28948151; PMCID: PMC5602801.
Copy Download .nbib Format: NLM
Treatment of Fetal Supraventricular Tachycardia.

Current treatment options in cardiovascular medicine

Zoeller BB.
PMID: 28265962
Curr Treat Options Cardiovasc Med. 2017 Jan;19(1):7. doi: 10.1007/s11936-017-0506-x.

OPINION STATEMENT: Fetal arrhythmia is a common reason for referral to fetal cardiology. Fetal supraventricular tachycardia can be subdivided into several groups with the most common being re-entrant supraventricular tachycardia and atrial flutter. Fetal tachycardia can lead to hydrops...

Cite
Zoeller BB. Treatment of Fetal Supraventricular Tachycardia. Curr Treat Options Cardiovasc Med. 2017;19(1):7doi: 10.1007/s11936-017-0506-x.
Zoeller, B. B. (2017). Treatment of Fetal Supraventricular Tachycardia. Current treatment options in cardiovascular medicine, 19(1), 7. https://doi.org/10.1007/s11936-017-0506-x
Zoeller, Bridget B. "Treatment of Fetal Supraventricular Tachycardia." Current treatment options in cardiovascular medicine vol. 19,1 (2017): 7. doi: https://doi.org/10.1007/s11936-017-0506-x
Zoeller BB. Treatment of Fetal Supraventricular Tachycardia. Curr Treat Options Cardiovasc Med. 2017 Jan;19(1):7. doi: 10.1007/s11936-017-0506-x. PMID: 28265962.
Copy Download .nbib Format: NLM
The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Arrhythmia & electrophysiology review

Lieve KV, Wilde AA, van der Werf C.
PMID: 27403293
Arrhythm Electrophysiol Rev. 2016 May;5(1):45-9. doi: 10.15420/aer.2016.3.3.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of...

Cite
Lieve KV, Wilde AA, van der Werf C. The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythm Electrophysiol Rev. 2016;5(1):45-9doi: 10.15420/aer.2016.3.3.
Lieve, K. V., Wilde, A. A., & van der Werf, C. (2016). The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythmia & electrophysiology review, 5(1), 45-9. https://doi.org/10.15420/aer.2016.3.3
Lieve, Krystien Vv, et al. "The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia." Arrhythmia & electrophysiology review vol. 5,1 (2016): 45-9. doi: https://doi.org/10.15420/aer.2016.3.3
Lieve KV, Wilde AA, van der Werf C. The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythm Electrophysiol Rev. 2016 May;5(1):45-9. doi: 10.15420/aer.2016.3.3. PMID: 27403293; PMCID: PMC4939313.
Copy Download .nbib Format: NLM
Flecainide: Current status and perspectives in arrhythmia management.

World journal of cardiology

Andrikopoulos GK, Pastromas S, Tzeis S.
PMID: 25717355
World J Cardiol. 2015 Feb 26;7(2):76-85. doi: 10.4330/wjc.v7.i2.76.

Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as...

Cite
Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76-85doi: 10.4330/wjc.v7.i2.76.
Andrikopoulos, G. K., Pastromas, S., & Tzeis, S. (2015). Flecainide: Current status and perspectives in arrhythmia management. World journal of cardiology, 7(2), 76-85. https://doi.org/10.4330/wjc.v7.i2.76
Andrikopoulos, George K, et al. "Flecainide: Current status and perspectives in arrhythmia management." World journal of cardiology vol. 7,2 (2015): 76-85. doi: https://doi.org/10.4330/wjc.v7.i2.76
Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85. doi: 10.4330/wjc.v7.i2.76. PMID: 25717355; PMCID: PMC4325304.
Copy Download .nbib Format: NLM
Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction.

HeartRhythm case reports

Pellizzón OA, Márquez MF, González MD, Nannini S, Leiva R, Catalano A, Iturralde P.
PMID: 28491747
HeartRhythm Case Rep. 2016 Aug 17;2(6):506-510. doi: 10.1016/j.hrcr.2016.08.001. eCollection 2016 Nov.

No abstract available.

Cite
Pellizzón OA, Márquez MF, González MD, et al. Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction. HeartRhythm Case Rep. 2016;2(6):506-510doi: 10.1016/j.hrcr.2016.08.001.
Pellizzón, O. A., Márquez, M. F., González, M. D., Nannini, S., Leiva, R., Catalano, A., & Iturralde, P. (2016). Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction. HeartRhythm case reports, 2(6), 506-510. https://doi.org/10.1016/j.hrcr.2016.08.001
Pellizzón, Oscar A, et al. "Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction." HeartRhythm case reports vol. 2,6 (2016): 506-510. doi: https://doi.org/10.1016/j.hrcr.2016.08.001
Pellizzón OA, Márquez MF, González MD, Nannini S, Leiva R, Catalano A, Iturralde P. Flecainide-induced incessant orthodromic atrioventricular reentrant tachycardia in Wolff-Parkinson-White syndrome: Uneven depression of accessory pathway conduction. HeartRhythm Case Rep. 2016 Aug 17;2(6):506-510. doi: 10.1016/j.hrcr.2016.08.001. eCollection 2016 Nov. PMID: 28491747; PMCID: PMC5419995.
Copy Download .nbib Format: NLM
Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics.

Journal of atrial fibrillation

Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P.
PMID: 28496906
J Atr Fibrillation. 2013 Dec 31;6(4):890. doi: 10.4022/jafib.890. eCollection 2013 Dec.

No published studies have evaluated the risks of cardiovascular (CV) events, stroke, congestive heart failure (CHF), interstitial lung disease (ILD), and severe acute liver injury (ALI) related to antiarrhythmics treatment in real-world clinical practice setting. We examined the relationship...

Cite
Gao S, Dai W, Zhang L, et al. Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. J Atr Fibrillation. 2013;6(4):890doi: 10.4022/jafib.890.
Gao, S., Dai, W., Zhang, L., Juhaeri, J., Wang, Y., & Caubel, P. (2013). Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. Journal of atrial fibrillation, 6(4), 890. https://doi.org/10.4022/jafib.890
Gao, Shujun, et al. "Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics." Journal of atrial fibrillation vol. 6,4 (2013): 890. doi: https://doi.org/10.4022/jafib.890
Gao S, Dai W, Zhang L, Juhaeri J, Wang Y, Caubel P. Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. J Atr Fibrillation. 2013 Dec 31;6(4):890. doi: 10.4022/jafib.890. eCollection 2013 Dec. PMID: 28496906; PMCID: PMC5153130.
Copy Download .nbib Format: NLM
QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists.

Journal of pharmacology & pharmacotherapeutics

Acosta-Materán C, Díaz-Oliva E, Fernández-Rodríguez D, Hernández-Afonso J.
PMID: 27440957
J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):102-5. doi: 10.4103/0976-500X.184776.

A high percentage of patients having atrial fibrillation (AF) presents with paroxysmal AF. Flecainide, the prototypic class Ic anti-arrhythmic drug is the most effective drug to maintain sinus rhythm in this subgroup of patients, though the drug has potential...

Cite
Acosta-Materán C, Díaz-Oliva E, Fernández-Rodríguez D, et al. QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. J Pharmacol Pharmacother. 2016;7(2):102-5doi: 10.4103/0976-500X.184776.
Acosta-Materán, C., Díaz-Oliva, E., Fernández-Rodríguez, D., & Hernández-Afonso, J. (2016). QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. Journal of pharmacology & pharmacotherapeutics, 7(2), 102-5. https://doi.org/10.4103/0976-500X.184776
Acosta-Materán, Carlos, et al. "QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists." Journal of pharmacology & pharmacotherapeutics vol. 7,2 (2016): 102-5. doi: https://doi.org/10.4103/0976-500X.184776
Acosta-Materán C, Díaz-Oliva E, Fernández-Rodríguez D, Hernández-Afonso J. QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):102-5. doi: 10.4103/0976-500X.184776. PMID: 27440957; PMCID: PMC4936076.
Copy Download .nbib Format: NLM
ECG findings in fatal flecainide intoxication.

BMJ case reports

Airaksinen KE, Koistinen MJ.
PMID: 21687216
BMJ Case Rep. 2009;2009:bcr2006108480. doi: 10.1136/bcr.2006.108480. Epub 2009 Feb 18.

No abstract available.

Cite
Airaksinen KE, Koistinen MJ. ECG findings in fatal flecainide intoxication. BMJ Case Rep. 2009;2009:bcr2006108480doi: 10.1136/bcr.2006.108480.
Airaksinen, K. E., & Koistinen, M. J. (2009). ECG findings in fatal flecainide intoxication. BMJ case reports, 2009bcr2006108480. https://doi.org/10.1136/bcr.2006.108480
Airaksinen, K E J, and Koistinen, M J. "ECG findings in fatal flecainide intoxication." BMJ case reports vol. 2009 (2009): bcr2006108480. doi: https://doi.org/10.1136/bcr.2006.108480
Airaksinen KE, Koistinen MJ. ECG findings in fatal flecainide intoxication. BMJ Case Rep. 2009;2009:bcr2006108480. doi: 10.1136/bcr.2006.108480. Epub 2009 Feb 18. PMID: 21687216; PMCID: PMC3106084.
Copy Download .nbib Format: NLM
Life-Threatening Errors With Flecainide Suspension in Children.

P & T : a peer-reviewed journal for formulary management

Grissinger M.
PMID: 29719362
P T. 2018 May;43(5):258-286.

Errors with flecainide suspension in children.

Cite
Grissinger M. Life-Threatening Errors With Flecainide Suspension in Children. P T. 2018;43(5):258-286
Grissinger, M. (2018). Life-Threatening Errors With Flecainide Suspension in Children. P & T : a peer-reviewed journal for formulary management, 43(5), 258-286.
Grissinger, Matthew. "Life-Threatening Errors With Flecainide Suspension in Children." P & T : a peer-reviewed journal for formulary management vol. 43,5 (2018): 258-286.
Grissinger M. Life-Threatening Errors With Flecainide Suspension in Children. P T. 2018 May;43(5):258-286. PMID: 29719362; PMCID: PMC5912238.
Copy Download .nbib Format: NLM
Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption.

Case reports in cardiology

De Schryver N, Hantson P, Haufroid V, Dechamps M.
PMID: 31428479
Case Rep Cardiol. 2019 Jul 24;2019:1905871. doi: 10.1155/2019/1905871. eCollection 2019.

A 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks. She was admitted to the Emergency Department for malaise and dizziness, and the electrocardiogram revealed...

Cite
De Schryver N, Hantson P, Haufroid V, et al. Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption. Case Rep Cardiol. 2019;2019:1905871doi: 10.1155/2019/1905871.
De Schryver, N., Hantson, P., Haufroid, V., & Dechamps, M. (2019). Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption. Case reports in cardiology, 20191905871. https://doi.org/10.1155/2019/1905871
De Schryver, Nicolas, et al. "Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption." Case reports in cardiology vol. 2019 (2019): 1905871. doi: https://doi.org/10.1155/2019/1905871
De Schryver N, Hantson P, Haufroid V, Dechamps M. Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption. Case Rep Cardiol. 2019 Jul 24;2019:1905871. doi: 10.1155/2019/1905871. eCollection 2019. PMID: 31428479; PMCID: PMC6681578.
Copy Download .nbib Format: NLM
Atrioventricular junctional tachycardia with exit block in an adolescent.

HeartRhythm case reports

Cundiff NM, Robinson JA, Cannon BC, Snyder CS.
PMID: 30581740
HeartRhythm Case Rep. 2018 Sep 21;4(12):594-597. doi: 10.1016/j.hrcr.2018.07.019. eCollection 2018 Dec.

No abstract available.

Cite
Cundiff NM, Robinson JA, Cannon BC, et al. Atrioventricular junctional tachycardia with exit block in an adolescent. HeartRhythm Case Rep. 2018;4(12):594-597doi: 10.1016/j.hrcr.2018.07.019.
Cundiff, N. M., Robinson, J. A., Cannon, B. C., & Snyder, C. S. (2018). Atrioventricular junctional tachycardia with exit block in an adolescent. HeartRhythm case reports, 4(12), 594-597. https://doi.org/10.1016/j.hrcr.2018.07.019
Cundiff, Nicholas M, et al. "Atrioventricular junctional tachycardia with exit block in an adolescent." HeartRhythm case reports vol. 4,12 (2018): 594-597. doi: https://doi.org/10.1016/j.hrcr.2018.07.019
Cundiff NM, Robinson JA, Cannon BC, Snyder CS. Atrioventricular junctional tachycardia with exit block in an adolescent. HeartRhythm Case Rep. 2018 Sep 21;4(12):594-597. doi: 10.1016/j.hrcr.2018.07.019. eCollection 2018 Dec. PMID: 30581740; PMCID: PMC6301910.
Copy Download .nbib Format: NLM
Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis.

European heart journal. Cardiovascular pharmacotherapy

Wilson H, Patton D, Moore Z, O'Connor T, Nugent L.
PMID: 32163173
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):363-372. doi: 10.1093/ehjcvp/pvaa018.

AIMS: To compare flecainide and dronedarone for sinus rhythm (SR) maintenance following electrocardioversion of persistent atrial fibrillation (AF), in patients with minimal or no structural heart disease.METHODS AND RESULTS: A systematic search of publications using EMBASE, CENTRAL, CINAHL, and...

Cite
Wilson H, Patton D, Moore Z, et al. Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):363-372doi: 10.1093/ehjcvp/pvaa018.
Wilson, H., Patton, D., Moore, Z., O'Connor, T., & Nugent, L. (2021). Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy, 7(5), 363-372. https://doi.org/10.1093/ehjcvp/pvaa018
Wilson, Hannah, et al. "Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis." European heart journal. Cardiovascular pharmacotherapy vol. 7,5 (2021): 363-372. doi: https://doi.org/10.1093/ehjcvp/pvaa018
Wilson H, Patton D, Moore Z, O'Connor T, Nugent L. Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):363-372. doi: 10.1093/ehjcvp/pvaa018. PMID: 32163173.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 180 entries